An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation

An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the...

Full description

Bibliographic Details
Main Authors: Xuemei Zhang, Qing Liu, Junhua Hu, Ling Xu, Wen Tan
Format: Article
Language:English
Published: Elsevier 2014-02-01
Series:Acta Pharmaceutica Sinica B
Subjects:
NGI
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383513001159
id doaj-7aa1a841ba1f4af48ba8e3d7231297d3
record_format Article
spelling doaj-7aa1a841ba1f4af48ba8e3d7231297d32020-11-25T01:01:06ZengElsevierActa Pharmaceutica Sinica B2211-38352211-38432014-02-0141798510.1016/j.apsb.2013.12.010An aerosol formulation of R-salbutamol sulfate for pulmonary inhalationXuemei Zhang0Qing Liu1Junhua Hu2Ling Xu3Wen Tan4School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaKey-Pharma Biomedical Inc., Dongguan 523000, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaAn aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.http://www.sciencedirect.com/science/article/pii/S2211383513001159R-salbutamolNebulizerNGIParticle sizeDose uniformityGuinea pigsAsthma
collection DOAJ
language English
format Article
sources DOAJ
author Xuemei Zhang
Qing Liu
Junhua Hu
Ling Xu
Wen Tan
spellingShingle Xuemei Zhang
Qing Liu
Junhua Hu
Ling Xu
Wen Tan
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
Acta Pharmaceutica Sinica B
R-salbutamol
Nebulizer
NGI
Particle size
Dose uniformity
Guinea pigs
Asthma
author_facet Xuemei Zhang
Qing Liu
Junhua Hu
Ling Xu
Wen Tan
author_sort Xuemei Zhang
title An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
title_short An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
title_full An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
title_fullStr An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
title_full_unstemmed An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
title_sort aerosol formulation of r-salbutamol sulfate for pulmonary inhalation
publisher Elsevier
series Acta Pharmaceutica Sinica B
issn 2211-3835
2211-3843
publishDate 2014-02-01
description An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.
topic R-salbutamol
Nebulizer
NGI
Particle size
Dose uniformity
Guinea pigs
Asthma
url http://www.sciencedirect.com/science/article/pii/S2211383513001159
work_keys_str_mv AT xuemeizhang anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT qingliu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT junhuahu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT lingxu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT wentan anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT xuemeizhang aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT qingliu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT junhuahu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT lingxu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
AT wentan aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation
_version_ 1725210839840980992